ACM
ALXN

Advent Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Advent Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-200
Closed -$25K – 322
2016
Q4 		$25K Buy
+200
New +$24.5K ﹤0.01% 248

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Advent Capital Management's ALXN Position: Q1 2018 in Review

Advent Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 10,958 shares — an estimated $1.31M sold.

Advent Capital Management first reported a position in ALXN in Q3 2013 and held it in 3 quarters. The position peaked at $1.86M in Q3 2013. 597 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • Advent Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Advent Capital Management sold 10,958 Alexion Pharmaceuticals shares in Q1 2018, an estimated $1.31M.
  • Advent Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 3 quarters.
  • Advent Capital Management's Alexion Pharmaceuticals position peaked at $1.86M in Q3 2013.
  • 597 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Advent Capital Management's 13F filing for Q1 2018, filed 11 May 2018.